Navigation Links
Purdue Pharma L.P. To Present Analysis Of Butrans® (buprenorphine) Transdermal System CIII Clinical Data At American Pain Society Annual Meeting
Date:5/18/2012

STAMFORD, Conn., May 18, 2012 /PRNewswire/ -- Purdue Pharma L.P. will present an analysis of data from completed clinical trials for Butrans® (buprenorphine) Transdermal System CIII at the American Pain Society's (APS) 31st Annual Scientific Meeting.
The analysis includes an evaluation of supplemental analgesic use and pain scores across the 7-day dosing interval.

(Logo: http://photos.prnewswire.com/prnh/20100921/NY67262 )

The poster will be presented at the APS meeting in Honolulu, HI on Friday, May 18 at 8:45 AM HAST: Butrans® (buprenorphine) Transdermal System and 7-day Analgesic Efficacy. M. Kwarcinski, M. Cataldo, C. Munera, B. Dain Poster #436.

Butrans is indicated for the management of moderate-to-severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.
Approved by the U.S. Food and Drug Administration (FDA) in June 2010, Butrans is the first transdermal system that delivers continuous release of the active ingredient, buprenorphine, for seven days.

Butrans is a Schedule III opioid prescription medication and can be abused in a manner similar to other opioid agonists, legal or illicit.  Working with the FDA, Purdue Pharma L.P. developed a Risk Evaluation and Mitigation Strategy (REMS) for Butrans that includes a Medication Guide, Elements to Assure Safe Use, such as a healthcare provider training guide, and a timetable for submitting assessments of the REMS.  This information is available at www.Butransrems.com.

Butrans is contraindicated in patients who have: significant respiratory depression, severe bronchial asthma, or known hypersensitivity to any of its components or the active ingredient, buprenorphine. Butrans is contraindicated in patients who have or are suspected of having paralytic ileus. 

Butrans is also contraindicated in the management of: acute pain or in patients who require opioid analgesia for a short period of time, postoperative pain, mild pain, or intermittent pain (e.g., use on an as-needed basis [prn]).

The Full Prescribing Information for Butrans contains the following Boxed Warning:WARNING: IMPORTANCE OF PROPER PATIENT SELECTION, POTENTIAL FOR ABUSE, AND LIMITATIONS OF USEProper Patient SelectionButrans is a transdermal formulation of buprenorphine indicated for the management of moderate-to-severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time.  Potential for Abuse Butrans contains buprenorphine which is a mu opioid partial agonist and a Schedule III controlled substance.  Butrans can be abused in a manner similar to other opioid agonists, legal or illicit.  Consider the abuse potential when prescribing or dispensing Butrans in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression).  Assess patients for their clinical risks for opioid abuse or addiction prior to being prescribed opioids.  Routinely monitor all patients receiving opioids for signs of misuse, abuse and addiction.  Limitations of UseDo not exceed a dose of one 20 mcg/hour Butrans system due to the risk of QTc interval prolongation.  Avoid exposing the Butrans application site and surrounding area to direct external heat sources.  Temperature dependent increases in buprenorphine release from the system may result in overdose and death.Warnings and Precautions

  • Respiratory Depression: Respiratory depression is the chief hazard with Butrans.  Use with extreme caution in patients at risk of respiratory depression.
  • CNS Depression: Butrans may cause somnolence, dizziness, alterations in judgment and alterations in levels of consciousness, including coma.  Use with caution in patients who are receiving other central nervous system (CNS) depressants.  Additive CNS effects are expected when used with alcohol, benzodiazepines, other opioids, or illicit drugs.
  • QTc Prolongation: Avoid in patients with Long QT Syndrome, family history of Long QT Syndrome, or those taking Class IA or Class III antiarrhythmic medications.
  • Head Injury:  Butrans may worsen increased intracranial pressure and obscure its signs, such as level of consciousness or pupillary signs.
  • Hypotensive Effects: Butrans may cause severe hypotension.  Use with caution in patients at increased risk of hypotension and in patients in circulatory shock.
  • Application Site Skin Reactions: In rare cases, severe application site skin reactions with signs of marked inflammation including "burn," "discharge," and "vesicles" have occurred.
  • Anaphylactic/Allergic Reactions: Cases of acute and chronic hypersensitivity to buprenorphine have been reported both in clinical trials and in the post-marketing experience.
  • Use in Pancreatic/Biliary Tract Disease and Other Gastrointestinal Conditions: Use with caution in patients with biliary tract disease, including acute pancreatitis.  Ileus may occur.  Monitor for decreased bowel motility.
  • Adverse Event InformationThe most common adverse reactions (>5%) included: nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash. 

    Butrans Transdermal System Dosages Three strengths of Butrans are commercially available by prescription in retail pharmacies nationwide: 5 mcg/hour (NDC code 59011-750-04); 10 mcg/hour (NDC code 59011-751-04); and 20 mcg/hour (NDC code 59011-752-04).  The maximum dose of Butrans is 20 mcg/hour.

    The Full Prescribing Information for Butrans, including the Medication Guide and Boxed Warning is available at www.purduepharma.com/PI/prescription/ButransPI.pdf and at www.butrans.com.About Purdue Pharma L.P.Purdue Pharma L.P. and its associated U.S. companies are privately-held pharmaceutical companies known for pioneering research on persistent pain.  Headquartered in Stamford, CT, Purdue Pharma is engaged in the research, development, production, and distribution of both prescription and over-the-counter medicines and hospital products.  Additional information about Purdue can be found at www.purduepharma.com.


    '/>"/>

    SOURCE Purdue Pharma L.P.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
    2. Purdue Pharma L.P. Provides Free Security Mobiles and Educational Safety Videos to Good Neighbor Pharmacy Members
    3. Purdue Pharma L.P. to Present Data From Clinical Program for Butrans™ (buprenorphine) Transdermal System CIII at PAINWeek® 2010
    4. NASCSA Receives $200,000 Grant From Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
    5. RxDrugSAFE™ Featured in National Campaign by Purdue Pharma and NCPA
    6. Purdue Pharma L.P. and the National Community Pharmacists Association Join Forces to Help Prevent Pharmacy Burglary
    7. Purdue Pharma L.P. Re-launches Partners Against Pain Website
    8. New Online Resource to Help Combat Abuse of Prescription Medications Launched by Purdue Pharma L.P.
    9. Purdue Pharmaceuticals Donates Medical Supplies to Protect Poor Children From Infection
    10. NASCSA Receives $200,000 Grant from Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
    11. NEA Health Information Network and Purdue Pharma L.P. Partner to Help Kids be Safe
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/27/2017)... Biophysics Corporation, a global medical device manufacturer based in ... growth in 2016 when compared to the previous year based ... fueled by its AffloVest® sales in the United ... global sales of surgical product lines. Said H. ... 25 th year in delivering high-quality, innovative medical devices ...
    (Date:2/27/2017)... (NASDAQ: IPXL ) today announced that it plans to participate ... James and Associates, 38 th Annual Institutional Investors Conference at ... Cowen and Company 37 th Annual ... Boston, MA. Barclays Global Healthcare ... FL. Individuals may listen to the ...
    (Date:2/27/2017)... Israel , Feb. 27, 2017 ... of adult stem cell technologies for neurodegenerative diseases, announced ... M.D., Ph.D., FACP, and Arturo O. Araya , ... "Dr. Almenoff and Mr. Araya are talented and ... time for our company," said Chaim Lebovits , ...
    Breaking Medicine Technology:
    (Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to a ... , Previous studies have provided evidence of a link between pesticides and incidence ...
    (Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert standing desk ... and advantages built into the home office sit stand solution are bold colors, ... to gain the benefits embedded in the TaskMate Go are available 24/7 through ...
    (Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official release of ... in Cannes (France), XO Private has initiated a second print-run of its lavish luxury ... a metre across when open, weighs in at more than six kilos, retails at ...
    (Date:2/24/2017)... ... ... An in-depth computational analysis of genetic variants implicated in both schizophrenia and ... may explain why susceptibility to one of the disorders could place individuals at lower ... the journal npj Schizophrenia. , “There is a wealth of genomic data on ...
    (Date:2/24/2017)... ... ... Smart Machine Age is here, and it’s disrupting everything. Not only could it drive ... United States may be taken over by technology in the next five to fifteen ... colleagues is drawing to a close. Success will belong to those who can quiet ...
    Breaking Medicine News(10 mins):